Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Rhea-AI Summary

Tempest Therapeutics (Nasdaq: TPST) will release new data from its global randomized Phase 1b/2 study of amezalpat (TPST-1120), combined with atezolizumab and bevacizumab, in the first-line treatment of hepatocellular carcinoma (HCC). The announcement will be made in a premarket press release on June 20, 2024, followed by a webcasted conference call at 8:30 a.m. ET. The study aims to explore the efficacy and safety of this combination therapy in treating HCC. Participants can join the conference call by pre-registering online to receive the necessary telephone number and unique passcode. The live webcast and a 30-day audio replay will be available on the Tempest website.

Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET

BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classⁱ targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global randomized Phase 1b/2 combination study of amezalpat (TPST-1120) with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m. ET.

To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the investor section of the Tempest website at https://ir.tempesttx.com/. The webcast will be available for replay for 30 days.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor & Media Contacts

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

i If approved by the FDA

FAQ

What is the focus of Tempest Therapeutics' new data release?

Tempest Therapeutics will release new data from their Phase 1b/2 study of amezalpat (TPST-1120) combined with atezolizumab and bevacizumab in first-line hepatocellular carcinoma (HCC).

When will Tempest Therapeutics announce the new data for TPST-1120?

Tempest Therapeutics will announce the new data on June 20, 2024, before the market opens.

How can I participate in the Tempest Therapeutics conference call?

You can participate by pre-registering online to receive a telephone number and unique passcode for the call.

Will the Tempest Therapeutics webcast be available for replay?

Yes, the webcast will be available for replay on the Tempest website for 30 days.

What is amezalpat (TPST-1120) being studied for?

Amezalpat (TPST-1120) is being studied in combination with atezolizumab and bevacizumab for the first-line treatment of hepatocellular carcinoma (HCC).